我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

血管重构在动脉型肺动脉高压中的研究进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第3期
页码:
361-364
栏目:
综述
出版日期:
2017-01-25

文章信息/Info

Title:
Advances in vascular remodeling of pulmonary arterial hypertension
作者:
董 昕; 刘 越; 张晓卉; 尹新华
哈尔滨医科大学附属第一医院心血管内科，黑龙江 哈尔滨 150001
Author(s):
DONG Xin;  LIU Yue;  ZHANG Xiao-hui;  YIN Xin-hua
Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China
关键词:
动脉型肺动脉高压; 血管重构; 病理机制; 药物治疗
Keywords:
pulmonary arterial hypertension;  vascular remodeling;  pathogenesis;  pharmacological treatment
分类号:
R543.2
DOI:
-
文献标识码:
A
摘要:
动脉型肺动脉高压(PAH)是以肺动脉压力持续升高、肺小动脉结构持续改变为特征的致命性疾病，肺动脉重构是其主要的病理学特点。许多研究发现PAH中血管重构的病理机制主要包括各种细胞的病理学改变和多种分子信号通路的参与，最新的研究指出表观遗传学也参与血管重构，从而导致疾病的发生发展。目前针对PAH发病机制的各种新型药物及新疗法正在被开发，其副作用更小、疗效更佳。本文重点阐述PAH中血管重构的病理机制包括病理学改变、新分子信号通路及表观遗传学内容，以及治疗的新进展。
Abstract:
Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a persistent elevation of pulmonary arterial pressure and persistent structural changes in small pulmonary arterioles. The main pathological feature is vascular remodeling of the pulmonary arteries. Many studies have suggested that its pathologic mechanism includes changes of various cells and several molecular signaling pathways. Recent research indicates that vascular remodeling also involves epigenetic components, resulting in the development of PAH. Various novel therapies targeting the pathological mechanism are being developed and designed to have fewer side effects and higher efficacy. This review focuses on the pathological mechanism including pathological changes, novel signaling pathways, and epigenetics as well as advances in treatment of PAH.

参考文献/References

[1]Benza RL,Miller DP,Gomberg-Maitland M,et al.Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management(REVEAL)[J].Circulation,2010,122(2):164-172.
[2]Good RB,Gilbane AJ,Trinder SL,et al.Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension[J].The Am J Pathol,2015,185(7):1850-1858.
[3]Xia Y,Fu Z,Hu J,et al.TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension[J].Am J Physiol Cell Physiol,2013 305(7):C704-C715.
[4]Kuhr FK,Smith KA,Song MY,et al.New mechanisms of pulmonary arterial hypertension:role of Ca2+signaling[J].Am J Physiol Heart Circ Physiol,2012,302(8):H1546- H1562.
[5]Thenappan T,Goel A,Marsboom G,et al.A central role for CD68(+)macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion[J].Am J Respir Crit Care Med,2011,183(8):1080-1091.
[6]Tian W,Jiang X, Tamosiuniene R,et al.Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension[J].Sci Transl Med,2013,5(200):200-117.
[7]Satoh K,Satoh T,Kikuchi N,et al.Basigin mediates pulmonary hy-pertension by promoting inflammation and vascular smooth muscle cell proliferation[J].Circ Res,2014,115(8):738-750.
[8]Montani D,Chaumais MC,Guignabert C,et al.Targeted therapies in pulmonary arterial hypertension[J].Pharmacol Ther,2014,141(2):172-191.
[9]Yamamura A,Ohara N,Tsukamoto K.Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension[J].PLoS ONE,2015,10(9):e0138384.
[10]Gangopahyay A,Oran M,Bauer EM,et al.Bone morphogenetic protein receptor II is a novel mediator of endothelial nitric-oxide synthase activation[J].J Biol Chem,2011,286(38):33134-33140.
[11]Long L,Ormiston ML,Yang X,et al.Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension[J].Nat Med,2015,21(7):777-785.
[12]ten Freyhaus H,Dumitrescu D,Berghausen E,et al.Imatinib mesylate for the treatment of pulmonary arterial hypertension[J].Expert Opin Investig Drugs,2012,21(1):119-134.
[13]Saco TV,Parthasarathy PT,Cho Y,et al.Role of epigenetics in pulmonary hypertension[J].Am J Physiol Cell Physiol,2014, 306(12):C1101-C1105.
[14]Lee A,McLean D,Choi J,et al.Therapeutic implications of microRNAs in pulmonary arterial hypertension[J].BMB Rep,2014,47(6):311-317.
[15]Courboulin A,Paulin R,Giguère NJ,et al.Role for miR-204 in human pulmonary arterial hypertension[J].J Exp Med,2011,208(3):535-548.
[16]Caruso P,Dempsie Y,Stevens HC,et al.A role for miR-145 in pul-monary arterial hypertension:evidence from mouse models and patient samples[J].Circ Res,2012,111(3):290-300.
[17]Sharma S,Umar S,Potus F,et al.Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing micro-RNA-193-3p[J].Circulation,2014,130(9):776-785.
[18]Bertero T,Lu Y,Annis S,et al.Systems-level regulation of microRNA networks by 130/301 promotes pulmonary hypertension[J].J Clin Invest,2014,124(8):3514-3528.
[19]Kim J,Hwangbo C,Hu X,et al.Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension[J].Circulation,2015,131(2):190-199.
[20]Zhao L,Chen CN,Hajji N,et al.Histone deacetylation inhibition in pulmonary hypertension:therapeutic potential of valproic acid and suberoylanilide hydro-xamic acid[J].Circulation,2012,126(4):455-467.
[21]O'Connell C,O’Callaghan DS,Humbert M.Novel medical therapies for pulmonary arterial Hyperten-Sion[J].Clin Chest Med,2013,34(4):867-880.
[22]Fares WH.Orenitram… Not verified[J].Am J Respir Crit Care Med,2015,191(6):713-714.
[23]Hamidi SA,Lin RZ,Szema AM,et al.VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension[J].Respir Res,2011,12:141.
[24]Panky EA,Thammasiboon S,Lasker GF,et al.Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat[J].Am J Physiol Heart Circ Physiol,2013,305(9):H1288-H1296.
[25]Klein M,Schermuly RT,Ellinghaus P,et al.Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experi-mental pulmonary hypertension and myocardial remodeling[J].Circulation,2008,118(20):2081-2090.
[26]张燕婷,熊旭东,王 倩,等.中医药治疗肺动脉高压研究现状[J].中国中医急症,2012,21(9):1467-1468.
[27]Takahashi M,Nakamura T,Toba T,et al.Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs[J].Tissue Eng,2004,10(5-6):771-779.
[28]Yen CH,Tsai TH,Leu S,et al.Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension[J].Cytotherapy,2013,15(2):209-223.
[29]Brock M,Samillan VJ,Trenkmann M,et al.AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension[J].European Heart Journal,2014,35(45):3203-3211.

备注/Memo

备注/Memo:
收稿日期：2015-11-12.通讯作者：尹新华，教授，主要从事高血压、冠心病及心衰基础和临床研究 Email:xinhua_yin@163.com 作者简介：董昕，硕士生 Email:dongxin8911@163.com
更新日期/Last Update: 2017-02-20